NCT04839016

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 660 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis

Conditions

• Moderate-to-Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	SHR-1314	SHR-1314
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-04-25
• Primary completion: 2023-08-30
• Completion: 2023-08-30
• First posted: 2021-04-09
• Last updated: 2021-04-09

Regulatory

• FDA-regulated drug study